乳腺癌
EZH2型
医学
肿瘤科
癌症
癌症研究
抗性(生态学)
内科学
生物
遗传学
表观遗传学
基因
生态学
作者
Y. Chen,Hongyan Zhu,Yuanyuan Luo,Shuangmei Tong,Yan Liang
标识
DOI:10.1016/j.biopha.2024.116624
摘要
Drug resistance presents a formidable challenge in the realm of breast cancer therapy. Accumulating evidence suggests that enhancer of zeste homolog 2 (EZH2), a component of the polycomb repressive complex 2 (PRC2), may serve as a key regulator in controlling drug resistance. EZH2 overexpression has been observed in breast cancer and many other malignancies, showing a strong correlation with poor outcomes. This review aims to summarize the mechanisms by which EZH2 regulates drug resistance, with a specific focus on breast cancer, in order to provide a comprehensive understanding of the underlying molecular processes. Additionally, we will discuss the current strategies and outcomes of targeting EZH2 using both single agents and combination therapies, with the goal of offering improved guidance for the clinical treatment of breast cancer patients who have developed drug resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI